Earnings Call Intelligence Subscribe
Home › Call Sheets › ELV › Q4'25
Call sheet · Q4'25

Elevance Health (ELV)

Q4'25 earnings call · held 2026-01-28 · compared with the Q3'25 call · management-credibility review
9/12
Disclosure score
2 high, 2 medium, 2 low flags
Financial quality
Bottom line
The One Big Beautiful Bill Act is the hidden catalyst that transforms Medicaid headwinds into tailwinds by removing unprofitable members through policy rather than ELV's own exits. Management's surgical Medicare pruning - losing high-teens membership while improving margins 200+ basis points - shows disciplined capital allocation finally working. The binding constraint isn't trend or rates, it's management credibility after the Medicare membership guidance miss. Quote: 'We believe this is manageable within the context of our diversified enterprise' - unusually confident for a company guiding to -1.75% Medicaid margins. My view changes if they can't deliver the promised 2027 earnings recovery or if 'nonrecurring' items keep recurring at this $3+ per share run rate.

The 30-second version

  • The One Big Beautiful Bill Act is the sleeper story nobody's talking about
  • Medicare margin improvement is real despite high-teens membership decline
  • The earnings baseline shell game hides deteriorating quality

What changed this quarter

MetricQ3'25Q4'25Change
Adjusted Diluted EPS$30.29 (2025 full year)$25.50+ guidance (2026)Down 16% before baseline adjustments
Medicare Advantage MembershipStable expectationsHigh teens percentage decline expectedSharp reversal from prior stability messaging
Medicare Operating MarginBelow target rangeAt least 2% target for 2026200+ bps improvement expected
Medicaid Operating MarginApproximately -50 bps (2025)Approximately -1.75% (2026)125 bps deterioration as guided
Total Medical Members45.2 million (Q4 2025)Low double-digit percentage decline expectedMembership contraction accelerating
Operating Cash Flow$4.3 billion (2025)$5.5+ billion (2026 guidance)28% improvement guided
Share Repurchases$2.6 billion (2025)$2.3 billion planned (2026)12% reduction in buyback capacity
Consolidated Medical Loss Ratio90.0% (2025 full year)90.2% ±50 bps (2026 guidance)20 bps deterioration at midpoint
Days in Claims Payable41.3 days (Q4)Low 40s range expectedStable reserve positioning
Long-term Enterprise Margin TargetNot specified5% to 6% (revised down)New lowered target framework

Accountability tracked

7 new promises made5 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full ELV Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.